Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.61 |
| ▸ | CDK2 | P24941 | 3/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148680 | 0.82 | CDK1 (0.57) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL4402870 | 0.82 | CDK1 (0.66) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL764036 | 0.81 | CDK1 (0.59) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL14131868 | 0.81 | CDK1 (0.64) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| 9-Methylguanine SCHEMBL2787045 | 0.81 | CDK1 (0.59) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL17226007 | 0.81 | CDK1 (0.55) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL129921 | 0.81 | CDK1 (1.00) | CDK1ADORA2AADORA1YTHDC1 | |
| SCHEMBL129640 | 0.81 | CDK1 (0.64) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL130527 | 0.81 | CDK1 (0.64) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL28782077 | 0.79 | CDK1 (0.66) | CDK1CCNB1CCNE1CDK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | claimed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-112209980-B | substituted purine nucleotides | 阿堤亚制药公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| EP-3728283-B1 | 3'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070026397-A1 | Method for producing second-generation library | NUEVOLUTION A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-20070026429-A1 | BINARY PROBE AND CLAMP COMPOSITION AND METHODS FOR TARGET HYBRIDIZATION DETECTION | APPLERA CORPORATION (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070026429-A1 | BINARY PROBE AND CLAMP COMPOSITION AND METHODS FOR TARGET HYBRIDIZATION DETECTION | APPLERA CORPORATION (US) | 2007-02-01 | — | — | US | disclosed |
| EP-0502690-B1 | Cyclopropane derivative | AJINOMOTO KK (JP) | 1999-12-01 | — | — | EP | disclosed |
| EP-0502690-A2 | Cyclopropane derivative | Ajinomoto Co., Inc. (JP) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | CDK1 4739/4885CCNB1 4816/4885CCNE1 4880/4885 |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | CDK1 141/4885CCNB1 343/4885CCNE1 175/4885 |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | CDK1 142/4885CCNB1 367/4885CCNE1 179/4885 |
| US-20070026429-A1 | BINARY PROBE AND CLAMP COMPOSITION AND METHODS FOR TARGET HYBRIDIZATION DETECTION | RNGTT, ADAR, FEN1 | CDK1 3427/4885CCNB1 2950/4885CCNE1 3306/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CDK1 3079/4885CCNB1 3030/4885CCNE1 2283/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | CDK1 86/4885CCNB1 526/4885CCNE1 533/4885 |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | CDK1 3236/4885CCNB1 4456/4885CCNE1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.